The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …
Novartis has won the backing of an FDA advisory committee for its chronic obstructive pulmonary disease (COPD) treatment QAB149. The …

Competition in the field of COPD and asthma is hotting up, with new data for several key treatments recently unveiled. …
A phase III treatment for COPD has demonstrated superior results over GSK’s established Serevent (salmeterol). Data from Novartis’ INSIST study …

